1. SWAG SSG Skin Cancer Meeting
Clinical Research Network
West of England
SWAG SSG Skin Cancer Meeting
Tuesday 16th May 2017
Research Report

2. Clinical Research Network & Cancer Services
West ofEngland
SWAG - Somerset Wiltshire Avon & Gloucestershire
South West Children’s Cancer & Leukaemia
Research Network

3. NIHR CRN High Level Objectives 2016-17
Increase number of participants into NIHR CRN portfolio studies
650,000 in England
21,905 in West of England
Increase the number of studies that deliver to time and target
Target 80%
Increase number of commercial studies delivered through network
Reduce NHS study set up times
Reduce time taken to recruit first participant

4. NIHR CRN Objectives for cancer 2016-17
Recruit 20% of cancer incidence
West of England 1,909
Recruit 7.5% of cancer incidence into interventional studies
716
Include challenging studies
Cancer surgery – 4 recruits per 100,000 population
Radiotherapy – 6 recruits per 100,000 population
Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population
Children & young people – 3 per 100,000 population
Teenagers & young adults – record number of year olds participating in research

7. Recruitment to Time and Target – Open Studies in May 2017

10. Cancer specialty objective for 2017-18
Number of LCRNs achieving on-target recruitment into at least 8 of the 13 Cancer subspecialties, where "on-target" means either improving recruitment by 10% from 2016/17 or meeting the following recruitment targets per 100,000 population served: 
a) Brain & CNS: 0.2; b) Breast: 8; c) Colorectal: 3; d) Paediatrics: 3; e) Gynae: 3; f) Head & Neck: 1; g) Haematology: 7; h) Lung: 4; i) Sarcoma: 0.1; j) Skin: 0.2; k) Supportive & Palliative Care and Psychosocial Oncology & Survivorship: 3; l) Upper GI: 3; m) Urology: 8.

11. 2016/17 YTD performance against 2017/18 Cancer specialty target

12. Open studies – Skin CPMS ID Study Title Project Status Site
Planned end date PI
18162
MelMarT - A Phase III, multicentre, multinational randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma. 
Suspended
North Bristol NHS Trust
01/01/2016
Wilson , Dr Ewan
19639
The PERM Study - Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
Open
University Hospitals Bristol NHS Foundation Trust
01/11/2018
Herbert, Dr Chris
32773
TRILOGY – A Phase III Study of Atezolizumab plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma.
31/08/2018

13. Studies in set up CPMS ID Study Title Site PI Summary 20444
RATIONAL MCC -
North Bristol NHS Trust
Challapalli, Dr Amarnath
A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC with an observational study for patients ineligible for the randomised trial.

14. Useful links https://www.crn.nihr.ac.uk/
National and local network information including training programmes templates, tools, contacts, videos etc
Open data platform. Look at performance across whole CRN including all specialty areas
View current national portfolio of open, closed and ‘in set up’ cancer studies
See where a study is open across the country
Search for a study to fit criteria. Good for horizon scanning, eligibility criteria

15. Contacts Research Delivery Manager – david.rea@nihr.ac.uk
Cancer portfolio facilitator –
Skin research lead –

16. Current Issues with Cancer Research
Gaps in the portfolio
Clinical pressures with some trial treatments
Pharmacy capacity issues
Extra time for administration of infusions
Extra length of treatment courses
Clinic space to see patients
Affordability to the NHS of the drugs we are researching
What should our regional portfolio look like?
Should we consider the whole region population when forecasting for trials?
Should we encourage more cross referral of patients for studies?
Should we select studies that will be more useful to the NHS?